Role of the cytokine profiles produced by invariant natural killer t cells in the initial phase of cyclophosphamide-induced tolerance

Transplantation

Volumn 86, Issue 9, 2008, Pages 1301-1310

  Onzuka, Tatsushi ^a   Tomita, Yukihiro ^a   Shimizu, Ichiro ^a   Okano, Shinji ^a   Yamada, Hisakata ^b   Yoshikai, Yasunobu ^b   Tominaga, Ryuji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Chimerism; Cytokine; NKT; Tolerance

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOLOGICAL TOLERANCE; LEUKOCYTE; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SKIN GRAFT; SPLEEN CELL; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DBA MOUSE; DOSE RESPONSE; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; MOUSE MUTANT; SKIN TRANSPLANTATION; SPLEEN;

ANIMALS; CHIMERA; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; GALACTOSYLCERAMIDES; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; SKIN TRANSPLANTATION; SPLEEN;

EID: 58149149953     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318187265e     Document Type: Article

References (52)

1. Bolman RM, Olivari MT, Saffitz J, et al. Current results with triple therapy for heart transplantation. Transplant Proc 1987; 19(1 pt 3): 2490.
2. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000.
3. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417.
4. Tomita Y, Yoshikawa M, Zhang QW, et al. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide. J Immunol 2000; 165: 34.
5. Zhang QW, Tomita Y, Matsuzaki G, et al. Heart allograft tolerance without development of posttransplant cardiac allograft vasculopathy in chimerism-based, drug-induced tolerance. Transplantation 2002; 73: 652.
6. Eto M, Mayumi H, Tomita Y, et al. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol 1990; 145: 1303.
7. Tomita Y, Nishimura Y, Harada N, et al. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion. J Immunol 1990; 145: 4026.
8. Tomita Y, Mayumi H, Eto M, et al. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloan-tigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J Immunol 1990; 144: 463.
9. Eto M, Mayumi H, Tomita Y, et al. Intrathymic clonal deletion of V beta 6 + T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens. J Exp Med 1990; 171: 97.
10. Mayumi H, Himeno K, Shin T, et al. Drug-induced tolerance to allografts in mice. IV. Mechanisms and kinetics of cyclophosphamide-induced tolerance. Transplantation 1985; 39:209.
11. Shin T, Mayumi H, Himeno K, et al. Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts. Transplantation 1984; 37: 580.
12. MaedaT, EtoM, NishimuraY, etal. Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming. Immunology 1993; 78: 113.
13. Eto M, Mayumi H, Tomita Y, et al. The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance. Eur J Immunol 1990; 20: 2005.
14. Iwai T, Tomita Y, Zhang QW, et al. Requirement of a higher degree of chimerism for skin allograft tolerance in cyclophosphamide-induced tolerance. Transpl Int 2005; 17: 795.
15. Iwai T, Tomita Y, Okano S, et al. Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance. J Immunol 2006; 177: 8400.
16. Iwai T, Tomita Y, Shimizu I, et al. The immunoregulatory roles of natural killer T cells in cyclophosphamide-induced tolerance. Transplantation 2007; 84: 1686.
17. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994; 180:1097.
18. Shimizu I, Tomita Y, Zhang QW, et al. Different expressions of Ly-49 receptors on mouse NK and NKT cells. Immunobiology 2001; 204:466.
19. Voyle RB, Beermann F, Lees RK, et al. Ligand-dependent inhibition of CD1d-restricted NKT cell development in mice transgenic for the activating receptor Ly49D. J Exp Med 2003; 197: 919.
20. Chiu YH, Jayawardena J, Weiss A, et al. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med 1999; 189: 103.
21. Jahng A, Maricic I, Aguilera C, et al. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199: 947.
22. Sidobre S, Naidenko OV, Sim BC, et al. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J Immunol 2002; 169: 1340.
23. Hayakawa Y, Godfrey DI, Smyth MJ. Alpha-galactosylceramide: Potential immunomodulatory activity and future application. Curr Med Chem 2004; 11: 241.
24. Halder RC, Aguilera C, Maricic I, et al. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 2007; 117:2302.
25. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, et al. alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000; 97: 8461.
26. Cui J, Shin T, Kawano T, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623.
27. Smyth MJ, Godfrey DI. NKT cells and tumor immunity - A double-edged sword. Nat Immunol 2000; 1: 459.
28. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052.
29. Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 2001; 7: 1057.
30. Seino KI, Fukao K, Muramoto K, et al. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci USA 2001; 98: 2577.
31. Ikehara Y, Yasunami Y, Kodama S, et al. CD4( + ) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest 2000; 105: 1761.
32. Griseri T, Beaudoin L, Novak J, et al. Invariant NKT cells exacerbate type 1 diabetes induced by CD8 T cells. J Immunol 2005; 175: 2091.
33. Yasunami Y, Kojo S, Kitamura H, et al. Valpha14 NK T cell-triggered IFN-gamma production by Gr-1 + CD11b + cells mediates early graft loss of syngeneic transplanted islets. J Exp Med 2005; 202: 913.
34. Kojo S, Seino K, Harada M, et al. Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J Immunol 2005; 175: 3648.
35. Jiang X, Kojo S, Harada M, et al. Mechanism of NKT cell-mediated transplant tolerance. Am J Transplant 2007; 7: 1482.
36. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087.
37. Parekh VV, Wilson MT, Olivares-Villagomez D, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115: 2572.
38. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. J Clin Invest 2005; 115: 2328.
39. Wilson MT, Johansson C, Olivares-Villagomez D, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100: 10913.
40. Godfrey DI, Kronenberg M. Going both ways: Immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004; 114: 1379.
41. Jiang X, Shimaoka T, Kojo S, et al. Cutting edge: Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 2005; 175:2051.
42. La Cava A, Van Kaer L, FuDongS. CD4+CD25+ Tregs and NKT cells: Regulators regulating regulators. Trends Immunol 2006; 27: 322.
43. Liu R, La Cava A, BaiXF, et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 2005; 175: 7898.
44. Crowe NY, Uldrich AP, Kyparissoudis K, et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003; 171:4020.
45. MatsudaJL, GapinL. Does the developmental status of Valpha14i NKT cells play a role in disease? Int Rev Immunol 2007; 26: 5.
46. Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat Rev Immunol 2007; 7: 505.
47. BenlaghaK, WeiDG, VeigaJ, et al. Characterization of the early stages of thymic NKT cell development. J Exp Med 2005; 202: 485.
48. McCaughtry TM, Wilken MS, Hogquist KA. Thymic emigration revisited. J Exp Med 2007; 204: 2513.
49. Berzins SP, McNab FW, Jones CM, et al. Long-term retention of mature NK1.1+ NKT cells in the thymus. J Immunol 2006; 176: 4059.
50. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515.
51. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741.
52. Ostrand-Rosenberg S, Clements VK, Terabe M, et al. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol 2002; 169: 5796.